DAWNZERA Trademark

Trademark Overview

On Monday, June 5, 2023, a trademark application was filed for DAWNZERA with the United States Patent and Trademark Office. The USPTO has given the DAWNZERA trademark a serial number of 98027559. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Wednesday, September 25, 2024. This trademark is owned by Ionis Pharmaceuticals, Inc.. The DAWNZERA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of edema, namely hereditary angioedema; pharmaceuticals in the fields of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders

General Information

Serial Number98027559
Word MarkDAWNZERA
Filing DateMonday, June 5, 2023
Status731 - SECOND EXTENSION - GRANTED
Status DateWednesday, September 25, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 21, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of edema, namely hereditary angioedema; pharmaceuticals in the fields of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSunday, July 9, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameIonis Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCarlsbad, CA 92010
Party NameIonis Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCarlsbad, CA 92010

Trademark Events

Event DateEvent Description
Thursday, June 8, 2023NEW APPLICATION ENTERED
Sunday, July 9, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, July 18, 2023ASSIGNED TO EXAMINER
Tuesday, July 18, 2023NON-FINAL ACTION WRITTEN
Tuesday, July 18, 2023NON-FINAL ACTION E-MAILED
Tuesday, July 18, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, October 16, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, October 16, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, October 16, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, October 16, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 1, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 21, 2023PUBLISHED FOR OPPOSITION
Tuesday, November 21, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 16, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 12, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, March 12, 2024SOU EXTENSION 1 FILED
Tuesday, March 12, 2024SOU EXTENSION 1 GRANTED
Wednesday, March 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 25, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, September 25, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 25, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, September 25, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, September 25, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, September 25, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, September 25, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, September 25, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, September 25, 2024SOU EXTENSION 2 FILED
Wednesday, September 25, 2024SOU EXTENSION 2 GRANTED

Related Keywords

dawnzera edema autosomal gastrointestinal ophthalmic pulmonary skin respiratory autoimmune disorders diseases